|1.||Radbruch, Lukas: 2 articles (01/2015 - 01/2010)|
|2.||Sangal, R Bart: 2 articles (03/2005 - 01/2004)|
|3.||Park, Yong-Moon Mark: 1 article (01/2015)|
|4.||Jerrell, Jeanette M: 1 article (01/2015)|
|5.||Mochamat: 1 article (01/2015)|
|6.||Cuhls, Henning: 1 article (01/2015)|
|7.||Mücke, Martin: 1 article (01/2015)|
|8.||Minton, Ollie: 1 article (01/2015)|
|9.||Peuckmann-Post, Vera: 1 article (01/2015)|
|10.||Stone, Patrick: 1 article (01/2015)|
|1.||Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
01/01/2000 - "Pemoline treatment of adolescents with attention deficit hyperactivity disorder: a short-term controlled trial."
06/01/1999 - "Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder."
08/01/1996 - "An open trial of pemoline in drug-dependent delinquents with attention-deficit hyperactivity disorder."
10/01/1995 - "This study uses auditory and visual P300 topography to develop a classification of attention deficit disorder (ADD), and to find predictors of treatment response to the stimulant pemoline. "
06/01/1995 - "Because pemoline has been widely used in recent years, further studies are needed to better quantify this risk in children with attention deficit-hyperactivity disorder."
12/01/1963 - "THE TRIAL OF A NEW STIMULANT, PEMOLINE, IN THE TREATMENT OF FATIGUE IN STUDENTS."
08/01/1992 - "Pemoline may be an effective short-term treatment for fatigue associated with MS, but its adverse effects are not well tolerated by many patients."
08/01/1992 - "Nineteen patients (46.3%) experienced excellent or good relief of fatigue with pemoline, and eight patients (19.5%) with placebo (p = 0.06, Fisher's exact test). "
01/01/1979 - "These differences proved the effectiveness of pemoline in combating symptoms of disturbances in concentration, memory, tension, depression and fatigue."
09/01/1978 - "Pemoline in the treatment of psychogenic fatigue in general practice."
08/01/1992 - "A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis."
10/01/1996 - "We present a case of pemoline-induced autoimmune hepatitis in a 46-yr-old woman who received the drug for management of her multiple sclerosis. "
02/01/1996 - "The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis."
11/01/1995 - "To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue. "
02/01/1996 - "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS. To our knowledge, these agents have never been compared in a placebo-controlled trial of patients with MS. To evaluate the effects of amantadine and pemoline on cognitive functioning in MS. A total of 45 ambulatory patients with MS and severe fatigue were treated for 6 weeks with amantadine, pemoline, or placebo using a parallel group design. "
01/01/1970 - "Morphology of Ehrlich tumor cells treated with magnesium pemoline and x-irradiation."
09/15/1969 - "Magnesium pemoline and Ehrlich tumor: tumor animal versus tumor cell survivals."
09/01/1996 - "This article discusses the use of psychostimulants, such as dextroamphetamine, methylphenidate, and pemoline, in a variety of illnesses, including depression in the medically ill, cancer, HIV, and AIDS. "
01/01/2015 - "We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis. "
09/01/2000 - "This article discusses the pharmacology of dextroamphetamine, methylphenidate, pemoline (and other psychostimulants such as caffeine and ephedrine), their use in general medicine and cancer care, side effects, and abuse potential. "
|5.||Substance-Related Disorders (Drug Abuse)
04/01/2004 - "This randomized, placebo-controlled trial, conducted between 1996 and 2000, evaluated the safety and efficacy of pemoline on substance abuse and conduct problems. "
04/01/2004 - "Pemoline was efficacious for ADHD but did not have an impact on CD or substance abuse in the absence of specific treatment for SUD."
06/01/1986 - "Drug dependence studies in animals have demonstrated that pemoline is not self-administered in naive nor cocaine-dependent animals. "
01/01/2015 - "The probability of a child with ADHD developing MDD was significantly associated with a comorbid anxiety disorder (aOR = 3.53), CD/ODD (aOR = 3.45), or a substance use disorder (aOR = 2.31); being female (aOR = 1.77); being treated with pemoline (aOR = 1.69), atomoxetine (aOR = 1.31), or mixed amphetamine salts (aOR = 1.28); a comorbid obesity diagnosis (aOR = 1.29); not being African American (aOR = 1.23), and being older at ADHD diagnosis (aOR = 1.09). "
|6.||Dopamine Agonists (Dopamine Agonist)